Low-cost generics a mixed blessing for diabetes treatment
July 12th 2011Low-cost generic drug programs pioneered by Wal-Mart and other big-box retailers are a mixed blessing for patients with diabetes. The loss-leader strategy used by big-box, chain, independent, and online pharmacies has boosted the mean cost of branded diabetes medications by up to 113% since 2008.
Innovative program establishes pharmacist as health coach, partner
July 12th 2011David D. Pope, PharmD, CDE, editor-in-chief of CreativePharmacist.com, has developed and directs an innovative, web-based program titled HealthyHeartClub.com, which offers accountability, encouragement, and education to help patients adopt healthier lifestyles and decrease cardiovascular risk.
Breaking news: FDA approves Boostrix to help prevent whooping cough in older adults
July 11th 2011FDA has approved Boostrix [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap); GlaxoSmithKline Biologicals] for use in adults aged 65 years and older for active booster immunization against tetanus, diphtheria, and pertussis (whooping cough). This approval makes Boostrix the first Tdap vaccine approved for use by this age group.
Breaking news: Multaq phase 3 study halts; increased cardiovascular events cited
July 8th 2011Dronedarone (Multaq, Sanofi), which is approved for nonpermanent atrial fibrillation (AF), was being tested on patients with permanent AF. However, that trial, PALLAS (Permanent Atrial fibrillation outcome Study using Dronedarone on top of standard therapy) phase 3b, has been terminated because it was causing increased cardiovascular events.
New evidence-based guidelines for PDN treatment
July 6th 2011In an effort to address the efficacy of various treatment options available to reduce pain and improve physical function and quality of life in patients with painful diabetic neuropathy, a broad literature review was conducted and new guidelines were published online May 17 in Neurology and were presented at the American Academy of Neurology Annual Meeting in Honolulu.
FDA approves Xarelto to help prevent DVT in patients undergoing knee- or hip-replacement surgery
July 6th 2011FDA has approved rivaroxaban tablets (Xarelto, Janssen Pharmaceuticals), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT), which may lead to a pulmonary embolism (PE) in people undergoing knee- or hip-replacement surgery. Xarelto is the only new oral anticoagulant with FDA approval for this indication.
Senate Community Pharmacy Caucus formed
July 6th 2011The first Senate Community Pharmacy Caucus was established in late June. Senator Jerry Moran (R-KS) and Senator Jon Tester (D-MT) created the caucus, which is meant to serve as an advocate for community pharmacy issues and as a clearinghouse of information for senators, staff, and other interested parties.
Breaking news: FDA approves only once-daily LABA for COPD
July 5th 2011FDA has approved once-daily indacaterol inhalation powder (Arcapta Neohaler, Novartis) 75 µg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta is not indicated for acute deteriorations of COPD or to treat asthma.
FDA's Hamburg to make final decision on Avastin's indication for metastatic breast cancer
July 1st 2011In the face of dozens of pink-clad demonstrators at the gates of FDA and many heartfelt pleas from women with metastatic breast cancer, an advisory committee to the agency voted unanimously at the end of June to hold firm in its recommendation that approval for Avastin (bevacizumab) for breast cancer be withdrawn.
Crizotinib treatment for ALK+ NSCLC shows early promise
June 30th 2011Crizotinib, an investigational drug, demonstrated an association with a sharp increase in survival rates for patients with advanced non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) positive genetic alteration, according to the results of an early-phase study presented at the 2011 annual meeting of the American Society of Clinical Oncology.
Intensive-dose statin therapy may increase diabetes risk
June 30th 2011Compared with moderate-dose therapy, intensive-dose statin therapy appears to be associated with increased risk of new-onset diabetes, concluded a meta-analysis of data from 5 statin trials published in the June 22/29 issue of JAMA.
Breaking news: FDA issues CRL for Remoxy, cites inconsistencies in its drug release performance
June 28th 2011Pfizer?s second attempt at an abuse-resistant formulation of oxycodone (Remoxy) recently received a complete response letter (CRL) from FDA. Just a week earlier, FDA approved another of the drug maker?s abuse-resistant products ? immediate-release Oxecta (oxycodone HCl) ? for the management of acute and chronic moderate-to-severe pain.
NCPA disputes PCMA claim about managed Medicaid savings
June 28th 2011Local pharmacists can reduce Medicaid costs by helping millions of patients take their medication properly, said B. Douglas Hoey, RPh, MBA, in a prepared statement of response to a recent ad campaign sponsored by the Pharmaceutical Care Management Association.
FDA calls for changes in ESA dosing for patients with chronic kidney disease
June 24th 2011FDA has announced more conservative dosing recommendations for erythropoiesis-stimulating agents (ESAs) when they are used to treat anemia in patients with chronic kidney disease (CKD) because of increased risk of cardiovascular events such as stroke, thrombosis, and death.
Breaking news: Southern California Kaiser pharmacists settle on new contract
June 24th 2011Kaiser Permanente pharmacists in Southern California have finally agreed to a new 3-year contract. The new terms were reached after an extended battle that saw pharmacists vote to strike, then reject what Kaiser called a final offer.
Longer-term use of pioglitazone associated with an increased risk of bladder cancer
June 23rd 2011FDA published an online safety communication on June 15, informing prescribers and patients that pioglitazone (Actos, Takeda Pharmaceuticals America Inc., Deerfield, Illinois) use may be associated with a 20% to 40% increased hazard of new bladder cancer.